A leading European firm of Intellectual Property specialists

We provide commercially focused, creative advice on obtaining, enforcing and exploiting intellectual property rights including patents, trade marks and designs to a wide range of clients who enjoy our straight forward approach and flexible working practices.

SPOTLIGHT ON...

150 Years of Innovation

From its small beginnings in 1867, Mewburn Ellis has grown into a vibrant, outward-looking partnership with innovation at its core. As science and technology continue to transform the way we live, we look forward to a future as positive and successful as our past.

Brexit

It's business as usual for Mewburn Ellis despite the decision for the UK to end its membership of the EU. We consider the effect of the decision on intellectual property.

Unitary Patent & the UPC

The Unitary Patent (UP) and Unified Patent Court (UPC) are due to come into entry in the near future and aim to bring a single patent right and single patent litigation forum to Europe.

MEDTECH

With a medtech team including patent attorneys drawn from all technical disciplines, you can rest assured that you will be working with a specialist that truly understands your technology.

PHARMACEUTICAL

The worldwide recognition achieved by our large pharmaceutical team will give you the confidence that your commercially valuable intellectual property is in the best hands.

FOOD & BEVERAGE

Many restaurateur, food producer and brewery clients have enjoyed considerable success working with our trade mark and patent attorneys to protect their brands and innovations.

OUR OFFICES

LONDON

t: +44 (0)20 7776 5300

BRISTOL

t: +44 (0)117 945 1234

CAMBRIDGE

t: +44 (0)1223 420383

MANCHESTER

t: +44 (0)161 247 7722

View map & contact details

LATEST NEWS & EVENTS

PATINEX 2017 (Patent Information Expo)

Stephen Hodsdon will be speaking about IP strategies in Europe after Brexit at the Patinex 2017 conference that takes place from 7 -8 September 2017 in Seoul, Korea.

Cambridge Enterprise signs deal with Qkine Ltd to drive stem cell and regenerative medicine research

Cambridge Enterprise, the commercialisation arm of the University of Cambridge, has licensed key technology to specialist growth factor manufacturer Qkine Ltd for Activin A production.